Literature DB >> 27035463

Acute Epidural Hematoma Formation in Cervical Spine After Interlaminar Epidural Steroid Injection Despite Discontinuation of Clopidogrel.

Ramsin M Benyamin1, Ricardo Vallejo, Victor Wang, Nitesh Kumar, David L Cedeño, Anobel Tamrazi.   

Abstract

BACKGROUND: Perioperative management of patients on anticoagulant therapy prior to interventional pain procedures creates a challenge when balancing the risk of bleeding against thromboembolic events. CASE REPORT: We report a case of epidural hematoma formation in the cervical spine following interlaminar epidural steroid injection in an elderly woman with chronic neck and arm pain, who was on clopidogrel therapy.
CONCLUSIONS: This is the first reported case of hematoma formation immediately following an epidural steroid injection possibly associated with clopidogrel, even though established guidelines on the timing of the discontinuation of clopidogrel prior to the procedure were exceeded. Severe pain appears to be the first symptom of hematoma formation, and therefore immediate diagnostic workup and evacuation of hematoma are essential in preventing neurological damage. It may be advisable to carry out a test specific for clopidogrel such as the P2Y12 to ensure that there is no residual action on platelet aggregation function, particularly in patients who may be slow metabolizers of clopidogrel. Caution is advised prior to administering analgesics with antiplatelet effects such as ketorolac.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27035463     DOI: 10.1097/AAP.0000000000000397

Source DB:  PubMed          Journal:  Reg Anesth Pain Med        ISSN: 1098-7339            Impact factor:   6.288


  2 in total

Review 1.  [Injection therapy for cervical and lumbar syndromes].

Authors:  J Grifka; A Benditz; D Boluki
Journal:  Orthopade       Date:  2017-02       Impact factor: 1.087

2.  [The application of different injection methods for cervical and lumbar syndromes].

Authors:  F Faber; A Benditz; D Boluki; J Grifka
Journal:  Schmerz       Date:  2018-02       Impact factor: 1.107

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.